Adalimumab for treating moderate to severe hidradenitis suppurativa

Equality Impact Assessment (Guidance development) (PDF 263 KB)

Final appraisal determination

Final appraisal determination document (PDF 453 KB)

Committee papers (PDF 9.52 MB)

Draft guidance: 1

Appraisal consultation document (PDF 460 KB)

Committee papers (PDF 8.72 MB)

Final scope (PDF 35 KB)

Final matrix (PDF 34 KB)

NICE's response to comments on the draft scope and provisional matrix (PDF 254 KB)

Equality impact assessment- scoping (PDF 62 KB)

Hidradenitis suppurativa (moderate, severe) - adalimumab: draft scope for consultation (pre-referral) - January 2015 (PDF 105 KB)

Hidradenitis suppurativa (moderate, severe) - adalimumab: provisional matrix (pre-referral) - January 2015 (PDF 43 KB)